Submit Your Feeds

Business News • PR NewsWire • Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO

Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO
Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO

OSLO, Norway, May 14, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that an abstract relating to the dose escalation part of the ONCOS-102 and durvalumab trial in...

View More : https://www.prnewswire.com:443/news-releases/targovax-announces-that-the-oncos-102-and-durvalumab-abstract-is-selected-f...
Releted News by prnewswire
Bigo Anuncia la campaña "Global BIGOer One World Together" en apoyo a quienes luchan contra la pandemia COVID-19
Life Science Tools Market Size Worth $84.4 Billion by 2026 | CAGR: 8.7%: Grand View Research, Inc.
Polyplastics lança nova grade de POM DURACON(R) com resistência melhorada a combustível diesel para componentes de combustível automotivo
Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO
GetUsPPE Announces Publication in The Lancet on Continued Healthcare PPE Shortage in the US
Honors Pathway's Dual Enrollment Program Expanded to All High School Seniors in Sonoma County Districts
Home Sitemap Contact Us
© businessNewsNewsNews.com